AG1 Announces Partnership with UC Davis to Advance Precision Health and Nutrition

2 MIN READ — 09/13/2025

Today, we’re proud to announce a partnership with UC Davis, one of the world’s leading research universities at the intersection of nutrition, health, and innovation, and widely recognized for advancing the “food as medicine” movement. In partnership with UC Davis and its Innovation Institute for Food and Health (IIFH), AG1 will explore new frontiers at the intersection of nutrition and metabolic health to pave the way for innovation in Precision Health and Nutrition. This approach integrates life sciences and data science to match nutrients from ingredients with the specific nutrition needs of targeted populations seeking to optimize their health and performance.

“UC Davis is world-renowned for its highly collaborative approach to driving breakthroughs in nutrition science,” said Kat Cole, CEO at AG1. “They are an important and valued strategic innovation partner for AG1 as we develop new products to help more people optimize their metabolic health and achieve their physical and mental performance potential.” 

This partnership builds on AG1’s extensive body of nutrition research, including recently concluded AG1 Next Gen clinical trials, and expands on the company’s continued investment in discovery research and thought leadership through collaborations with top institutions and accredited universities in the U.S., including Hofstra University, Kent State University, Texas Tech University, and University of Arkansas for Medical Sciences.

“AG1 is a pioneer in the category of nutrition as they embrace complexities in 21st century nutrition innovation through a science-led approach,” said Dr. Justin Siegel, Faculty Director of the IIFH and Professor of Chemistry, Biochemistry and Molecular Medicine at UC Davis. “AG1 is an outstanding partner as we pursue breakthroughs at the intersection of nutrition and metabolic health that leverage world-class capabilities, such as the Periodic Table of Food Initiative we developed with the Rockefeller Foundation and the American Heart Association.” 

AG1 products are designed by an in-house team of scientists, researchers, and nutritionists, and are continuously updated to reflect the latest scientific research to help meet people’s unique health goals. Driven by a core value of continuous improvement, AG1 is committed to raising the standard for quality, efficacy, and third-party testing.

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Information on this site is provided for informational purposes only. It is not meant to substitute for medical advice from your physician or other medical professional. You should not use the information contained herein for diagnosing or treating a health problem or disease, or prescribing any medication. Carefully read all product documentation. If you have or suspect that you have a medical problem, promptly contact your regular health care provider.

** AG1 Welcome Kit Offer valid for new AG1 subscribers only. AGZ frother Offer valid for first AGZ order only.

Actual Packaging May Vary

Free shipping for new U.S. customers only.

  1. In a triple-blind, randomized, placebo-controlled parallel-designed clinical trial evaluating nutrient biomarkers and microbiome shifts in 105 healthy adults ages 20-59 over the course of 12 weeks.
  2. In a double-blind, randomized, placebo-controlled 2-week crossover clinical trial assessing nutrient gaps and microbiome shifts in 20 active adults ages 19-37.
  3. In a double-blind, randomized, placebo-controlled 2-week crossover clinical trial assessing nutrient gaps and microbiome assessments of 24 healthy adults with occasional GI distress ages 26-59 over the course of 4 weeks.
  4. In a double-blind, randomized, placebo-controlled crossover clinical trial assessing nutrient gaps and bioavailability in 16 healthy adults ages 18-42 over the course of 8 hours.
  5. In a third-party, single-arm, closed label interventional study of 104 healthy adults ages 25-59 assessing self-perceived efficacy of AG1 Next Gen over 3 months.